OLYMPUS
14.9.2022 03:01:37 CEST | Business Wire | Press release
Olympus Corporation (“Olympus” - Director, Representative Executive Officer, President and CEO: Yasuo Takeuchi) today announced the launch of VISERA ELITE III, its newest surgical visualization platform that addresses the needs of healthcare professionals (HCPs) for endoscopic procedures across multiple medical disciplines. VISERA ELITE III offers various imaging functions, all supported in one system enabling minimally invasive therapies such as Laparoscopic Colectomy and Laparoscopic Cholecystectomy. Future software upgrades will advance surgical imaging technology and allow for individual configurations that facilitate seamless support of various surgical applications leading to a reduction in investment costs. VISERA ELITE III will be available in Europe, Middle East and Africa (EMEA), parts of Asia, Oceania, and Japan in September 2022 or later.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005632/en/
Surgical visualization platform VISERA ELITE III (Photo: Business Wire)
“With VISERA ELITE III, we provide a best-in-class surgical visualization platform designed for multiple medical specialties and configurations, allowing HCPs to fully focus on the patient during surgery. By incorporating the technologies of its predecessors VISERA ELITE II and VISERA 4K UHD into one platform, VISERA ELITE III enhances the quality of endoscopic surgery, contributes to improved efficiency in the operating room, and hereby elevates the standard of care,” said Kanichi Matsumoto, Global Head of Surgical Endoscopy at Olympus.
One System for All
VISERA ELITE III system integrates the 3D and infrared1 imaging functions from VISERA ELITE II, and the 4K imaging function from VISERA 4K UHD system. It also supports fluorescence guided surgery as well as NBI2, a unique observation mode developed by Olympus. By providing surgeons with multiple observation modes, the all-in-one system supports standardization and increases efficiency in the operating room. Users can also set up customized departmental profiles on VISERA ELITE III for different medical disciplines such as general surgery, urology, gynecology, ENT surgery and more. The platform is compatible with existing endoscopes from VISERA ELITE II.
Innovation That Grows with Need
The platform allows software upgrades to add new surgical imaging functions as needed. Switching entire surgical visualization systems to access the latest technology is no longer necessary, which not only sets a new standard and provides a high degree of flexibility, but also makes VISERA ELITE III a future-proof investment.
Improved Image Quality for More Focus
VISERA ELITE III system comes with a focus adjust mode during 4K surgical observation and is equipped with the EDOF (Extended Depth of Field) function that allows precise endoscopic observations through continuous broad focus and seamless magnification. In addition, it provides the C-AF (Continuous Auto Focus) capability that automatically adjusts focus in accordance with the movement of the camera head and endoscope. This facilitates clearer image capture, both up close and at a greater distance, so that HCPs experience less stress during surgery, allowing them to concentrate on the patient and the procedure's outcome.
VISERA ELITE III combines Sony Corporation’s state-of-the-art digital imaging technologies with the expertise and experience in medical product development that Olympus has accumulated over decades as a leading endoscope manufacturer and addresses the growing needs of hospitals as recognized through extensive exchange with customers.
In developing VISERA ELITE III, Sony Olympus Medical Solutions, a joint venture company of Sony and Olympus, optimized each technology and image processing function specifically for medical applications to create the most advanced, open, and versatile surgical visualization platform Olympus has ever brought to market.
About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety.
In its Endoscopic Solutions business, Olympus uses innovative capabilities in medical technology, therapeutic intervention and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic and minimally invasive procedures to improve clinical outcomes, reduce overall costs and enhance the quality of life for patients. Starting with the world’s first gastrocamera in 1950, Olympus’ Endoscopic Solutions portfolio has grown to include endoscopes, laparoscopes, and video imaging systems, as well as customer solutions and medical services. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp.
Note: Products or devices presented include future technology which may be pending regional regulatory approval and are not available for sale in all regions.
______________________________
1 Infrared imaging is a special light observation function for observing the fluorescence generated by administering a fluorescent agent called indocyanine green (ICG) and by applying near-infrared light (light with a wavelength of 700-780 nm).
2 NBI (Narrow Band Imaging) is an imaging technique for examining features such as the small blood vessels in mucosa and the surface patterns. NBI highlights tissue by illuminating it with two narrow bands (wavelengths) of light that are absorbed by the hemoglobin in blood.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005632/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
vVARDIS Announces Pricing of Initial Public Offering13.11.2026 06:02:00 CET | Press release
vVARDIS Holding AG (“vVARDIS”), a Swiss healthcare company operating in the dental med-tech sector, today announced the pricing of its initial public offering of 9,722,223 Class A ordinary shares at a public offering price of $18.00 per share. In connection with the offering, vVARDIS has granted the underwriters a 30-day option to purchase up to an additional 1,458,333 Class A ordinary shares at the initial public offering price to cover over-allotments. The Class A ordinary shares are expected to begin trading on the New York Stock Exchange on November 13, 2026 under the symbol “VVVV.” The closing of the offering is expected to occur on or about November 16, 2026 subject to the satisfaction of customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan are acting as joint bookrunning managers for the offering, with William Blair, UBS Investment Bank and Deutsche Bank Securities acting as bookrunners. A registration statement on Form F-1 relating to the offering has been file
Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4*12.11.2026 23:07:00 CET | Press release
The multi-level takeover includes a Throne Room, interactive photo opportunities, special lighting, and more The Empire State Building (ESB) is the gateway to Mount Olympus in Percy Jackson’s world, and now fans can experience the magic like never before. On Nov. 16, the Empire State Building Observation Deck (ESBOD) will unveil “Olympus Awaits,” a multi-level “Percy Jackson and the Olympians” takeover, in partnership with Disney+. The immersive takeover – included with every Observation Deck ticket – will feature an epic Throne Room, interactive photo opportunities, surprise giveaways, ESB x “Percy Jackson” merch, and more, available through Dec. 4, 2026.* This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112442266/en/ Empire State Building Observation Deck to Debut ‘Olympus Awaits,’ An Immersive ‘Percy Jackson and the Olympians’ Takeover in the Heart of NYC, On Display from Nov. 16 – Dec. 4* “This immersive NYC experience
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 18:09:00 CET | Press release
Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 18:00:00 CET | Press release
New feature lets members follow friends and family, share performance and health insights, and celebrate life's moments together WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
